Almost five years after Seres Therapeutics slammed into a Phase II failure with its lead candidate, the microbiome pioneer is reporting another massive flop in ulcerative colitis. But like the last time, the company isn’t throwing in the towel just yet. Patients who took SER-287 — a consortia of bacteria

.@VedantaBio closes $68M #SeriesD #financing to advance defined #bacterial consortiaTargeting Ph3 #ClinicalTrials in patients at high risk of recurrent #Cdiff #infection; Ph2 study in #UlcerativeColitishttps://t.co/bj7jwfV4sW#microbiome #microbiota @WestwickeIR @bernatolle pic.twitter.com/8T1RY93fwV— DDNews Online (@DDNewsOnline) July 21, 2021

C. difficile is the most common cause of antibiotic-associated diarrhea in developed countries. New findings may help treat and even prevent it.

Read it now on PracticeUpdate.com

Novome Biotechnologies' first engineered bacteria treatment, designed to colonize the gut and degrade excessive amounts of oxalate in the gut of individuals with the kidney condition enteric hyperoxaluria, has started human trials.

Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action...

Australian Biopharmaceutical Research

The company’s RBX2660, administered as a single dose, demonstrated superiority over standard of care for reducing Clostridioides difficile infection (CDI) recurrence.

Acurx Pharmaceuticals, Inc.  announced today that it has filed a provisional patent application in the United States Patent and Trademark Office (USPTO).

Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a provisional patent application in the United States Patent and Trademark Office (USPTO). The filing of this patent application relates to ibezapolstat and its use to treat C. difficile Infection while reducing the recurrence of the infection, as well as improving the h

💬 "It was very important to me that we made it one club."Owner @SandgaardThomas spoke to players and staff as the club embarks on an exciting new journey... #cafc #cafcwomen pic.twitter.com/jn4IfRNbnd— Charlton Athletic Women (@CAFCWomen) July 6, 2021

Ex-Charlton Athletic defender Brendan Wiredu has signed a new two-year deal with Colchester United, as announced by their club website.

FDA has granted Fast Track designation for ACX-362E, an investigational new treatment for C diff that is being developed by Acurx Pharmaceuticals, LLC.

PureTech Health plc is pleased to note that its Founded Entity, Vedanta Biosciences, announced additional results from a Phase 1 study in healthy volunteers of VE202, Vedanta’s 16-strain live biotherapeutic product candidate for inflammatory bowel disease.

Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific...

Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a Phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of CDI (Clostridioides difficile Infection) recurrence were associated with ibezapolstat compared to vancomycin. These results were presente

Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. Difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million in upfront and contingent milestone payments Seres Therapeutics to conduct a conference call at 8:30 a.m. ET

New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge.

Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile infections.

Nestlé Health Science will help Seres Therapeutics bring its microbiome drug candidate to the U.S. market, per a new deal announced Thursday.

After a rough couple of years, things are looking up for Seres Therapeutics. The microbiome company’s partner Nestlé Health Sciences is handing over $175 million upfront to help market its lead microbiome treatment in North America.

ADELAIDE, South Australia, June 30, 2021--Australian biotech company BiomeBank submits for Market Authorisation of their microbial product for Clostridioides difficile and Ulcerative Colitis.

Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a Phase 1 study in healthy volunteers of VE202, the Company’s 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).